Novel agents in trials for AML: quizartinib and gilteritinib

Novel agents in trials for AML: quizartinib and gilteritinib

VJHemOnc

1 year
239 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
Report 0 0
Category:
Description:
At the 2018 European School of Haematology (ESH) Clinical Updates on Acute Leukaemias, held in Budapest, Hungary, Mark Levis, MD, PhD, from Sidney Kimmel Comprehensive Cancer Centre, Baltimore, MD, gives us an update on novel chemotherapeutic agents for acute myeloid leukemia (AML). The majority of these novel agents target either FLT3 or IDH, such as midostaurin, quizartinib and gilteritinib, which are being tested at every disease stage. Although promising results have been produced, there has been resistance through signaling pathways such as Ras; thus, these agents may require testing in combination regimens.
Up Next Autoplay